SCHEMBL1629267

SCHEMBL1629267

O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(OC(F)F)cc1)N1CCCC1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
DAGLA Q9Y4D2 2/20 0.44
DAGLB Q8NCG7 1/20 0.44
OXTR P30559 3/20 0.43
AVPR1A P37288 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
PKM P14618 1/20 0.43
NR3C1 P04150 1/20 0.43
PGR P06401 1/20 0.43
LMNA P02545 2/20 0.42
ALOX5 P09917 1/20 0.42
HSD11B1 P28845 1/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
UTS2R Q9UKP6 1/20 0.41
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630085 0.92 CRHBP (0.45) CRHBPCRHR2DAGLADAGLBOXTR
SCHEMBL1630616 0.90 CRHBP (0.53) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL1629236 0.89 CRHBP (0.56) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL1630682 0.88 CRHBP (0.47) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL1630642 0.88 CRHBP (0.51) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL3422507 0.88 CRHBP (0.51) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL1630968 0.86 OXTR (0.53) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL8060525 0.86 CRHBP (0.55) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL3423076 0.84 CRHBP (0.49) CRHBPCRHR2OXTRAVPR1ANPSR1
SCHEMBL1629046 0.84 OXTR (0.60) CRHBPCRHR2OXTRAVPR1ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245006-B1 SULFONAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-06-01 EP disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPSR1 CRHBP 170/4885CRHR2 14/4885DAGLA 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.